TSE:TR Trillium Therapeutics (TR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Trillium Therapeutics Stock (TSE:TR) Get Trillium Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,075 shsAverage Volume99,071 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Troubadour Resources Inc. is a North American mineral acquisition and exploration company focused on the development of quality critical metal properties that are drill-ready with high-upside and expansion potential. Based in Vancouver, BC British Columbia, Troubadour's portfolio of strategic properties provides target-rich diversification and includes the Senneville Copper-Gold VMS project in Quebec, and the Amarillo Copper Porphyry and Texas Silver-Gold Projects in BC British Columbia. Troubadour trades on the TSX Venture Exchange under the symbol 'TR' and the OTC Market under the symbol 'TROUF'. Read More Receive TR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TR Stock News HeadlinesEvaxion Appoints Helen Tayton-Martin As Chief ExecutiveOctober 28, 2025 | msn.comTargeted Alpha Therapy Market 2028December 12, 2024 | finance.yahoo.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsOctober 1, 2024 | markets.businessinsider.comKabete National Polytechnic Ranked Best TTI in New Timely Kenya SurveyMay 28, 2024 | msn.comPension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest fundsMay 28, 2024 | theglobeandmail.comNimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, OncologyMay 7, 2024 | finance.yahoo.comRatio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating OfficerMay 6, 2024 | finance.yahoo.comSee More Headlines TR Stock Analysis - Frequently Asked Questions How do I buy shares of Trillium Therapeutics? Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include Defiance Trillion Dollar Club Index ETF (TRIL), Advanced Micro Devices (AMD), Six Flags Entertainment (FUN), Mind Medicine (MindMed) (MNMD), NIO (NIO), Siyata Mobile (SYTA) and Industry, Sector and Symbol Stock ExchangeTSE SectorManufacturing Industry Sugar And Confectionery Products Sub-IndustryFood Products Current SymbolTSE:TR CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployees2,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (TSE:TR) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.